

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

2014 THIRD QUARTERLY REPORT

13.09(2) 13.10B (C . 571

2014

“Company” “Fosun Pharma”, (“Group”).

C A B

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu
Chairman

28 2014

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Wang Pinliang, Ms. Kang Lan and Mr. John Changzheng Ma; and the independent non-executive directors of the Company are Mr. Han Jiong, Dr. Zhang Weijiong, Mr. Li Man-kiu Adrian David and Mr. Cao Huimin.

* for identification purposes only

1. IMPORTANT NOTICE

$1.1T$

1.2 A  C  B 

1.3 , f

A B f (A C , ff) ff

1.4T  

2.1 $\mathbf{f}$ $\mathbf{f}$

	As at the end of the Reporting Period	As at the end of the previous year	Change recorded at the end of the Reporting Period compared with the end of the previous year (%)
As at the end of the Reporting Period	33,238,438,720.78	29,475,190,861.78	12.77
()	16,776,036,218.20	15,332,184,483.03	9.42
	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)	Year-on-year change (%)
	843,637,595.71	467,404,025.74	80.49
	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)	Year-on-year change (%)
	8,661,444,631.29	7,070,780,938.31	22.50
(1)	1,574,583,864.38	950,584,632.64	65.64
	1,050,763,440.19	770,933,187.12	36.30
(%) (2)	9.43	6.94	2.49
B (B/) (2)	0.69	0.42	64.29
D (B/) (2)	0.69	0.42	64.29

– 3 –

	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)	Year-on-year change (%)
Operating income	1,551,015,043.85	1,389,079,631.65	11.66
Operating expenses	1,050,763,440.19	770,933,187.12	36.30
Operating profit	500,251,603.66	618,146,444.53	-19.07

Note 2: The company's operating income, operating expenses, and operating profit are calculated based on the company's accounting policy. The company's operating income, operating expenses, and operating profit are calculated based on the company's accounting policy. The company's operating income, operating expenses, and operating profit are calculated based on the company's accounting policy.

•

•

C.

$$\vdots$$
[illegible]

[illegible]

The Top 10 unrestricted shareholders of tradable shares			
Name of the shareholders	Number of unrestricted tradable shares held	Type and number of shares	
		Type	Number
T () C . .	920,641,314	B	920,641,314
CC T (Note)	402,556,100		402,556,100
104	35,389,831	B	35,389,831
— 001 C . . — — 018	19,661,022	B	19,661,022
118	16,370,437	B	16,370,437
C C B — A	15,000,000	B	15,000,000
T	12,000,000	B	12,000,000
C C B —	8,972,515	B	8,972,515
() C . .	8,638,672	B	8,638,672
C C B — A	8,306,151	B	8,306,151
	C C B — A C B C T C C f f C		

Note: CC f T, A C C ,

3.2 A

√ A □ A

1. 6 A 2012, 2012 C ,
C
f B2
f T C 31 f 2012 T C
2012 2014, f C 2014 (“C
B1
f 365 f C B100 5.15% T
C
C
2. 18 A 2014, (“ ”) f C
C (“C ”) f 30%
22 C B
C () T C ”),
C “ ”,
A
\$24.00 f
\$223.62 3,157,163
18 A 2014 (T), T
C f C 30%
2013 A C 30 2014 T
(T), 29 2014

B^f_f 1 f 2014,

A A B.

2 —

2014,

B1,206,443,978.57

B991,621,088.37

T

B^f 1 2014,

A A B.

2 —

C (f

2014,

(f),

(f)

f'

f' ff

T

2014

: C : B

Retrospective Effect on the Consolidated Income Statement						
Accounting Items	January – September 2014			January – September 2013		
	Amounts before retrospective adjustments	Adjustment amounts	Amounts after retrospective adjustments	Amounts before retrospective adjustments	Adjustment amounts	Amounts after retrospective adjustments
	1,431,475,082.58	31,425,094.04	1,462,900,176.62	1,383,399,844.53	–584,659,998.68	798,739,845.85
	302,125,147.84	7,856,273.51	309,981,421.35	313,206,671.22	–146,164,999.67	167,041,671.55
	1,551,015,043.85	23,568,820.53	1,574,583,864.38	1,389,079,631.65	–438,494,999.01	950,584,632.64
	1,050,763,440.19	—	1,050,763,440.19	770,933,187.12	—	770,933,187.12
	500,251,603.66	23,568,820.53	523,820,424.19	618,146,444.53	–438,494,999.01	179,651,445.52
Retrospective Effect on the Consolidated Balance Sheet						
Accounting Items	30 September 2014			1 January 2014		
	Book value before retrospective adjustments	Adjustment amounts	Book value after retrospective adjustments	Book value before retrospective adjustments	Adjustment amounts	Book value after retrospective adjustments
C	4,319,603,703.62	2,943,813,173.78	7,263,416,877.40	4,501,744,912.27	2,967,381,994.31	7,469,126,906.58
	8,663,707,568.04	–2,943,813,173.78	5,719,894,394.26	7,112,692,524.18	–2,967,381,994.31	4,145,310,529.87

(1)

: C : B

Investee	Basic information of the transaction	Equity attributable to the shareholders of the parent company as at 1 January 2013 (+/-)	31 December 2013		
			Long-term equity investment (+/-)	Long-term equity investment (+/-)	Equity attributable to the shareholders of the parent company (+/-)
	7.97%	–	–261,229,093.17	261,229,093.17	–
豪同投資發展有限公司 (深圳市豪同投資發展有限公司)	18.00%	–	–148,990,000.00	148,990,000.00	–
B	19.971%	–	–138,750,292.58	138,750,292.58	–
C 司, (青島亨達股份有限公司)	15.00%	–	–118,530,000.00	118,530,000.00	–
A 南亞洲製藥有限公司 () C 司, (海南亞洲製藥有限公司)	10.19%	–	–113,850,000.00	113,850,000.00	–
		–	–210,271,702.62	210,271,702.62	–
T		–	–991,621,088.37	991,621,088.37	–

Investee	Basic information of the transaction	Equity attributable to the shareholders of the parent company as at 1 January 2014 (+/-)	30 September 2014		
			Long-term equity investment (+/-)	Long-term equity investment (+/-)	Equity attributable to the shareholders of the parent company (+/-)
	7.97%	—	-261,229,093.17	261,229,093.17	—
黃海製藥有限責任公司	5.00%	—	-201,180,000.00	201,180,000.00	—
（深圳市豪同投資發展有限公司）	18.00%	—	-148,990,000.00	148,990,000.00	—
B	19.97%	—	-138,750,292.58	138,750,292.58	—
C 。（青島亨達股份有限公	15.00%	—	-118,530,000.00	118,530,000.00	—
司）					
A （ ）C 。（海	10.19%	—	-113,850,000.00	113,850,000.00	—
南亞洲製藥有限公司）					
		—	-223,914,592.82	223,914,592.82	—
T		—	-1,206,443,978.57	1,206,443,978.57	—

(1)

B 1 2014, , A

B. 2 —

(2)

Investees	Basic information of the transaction	1 January 2014		30 September 2014	
		Capital reserve (+/-)	Retained profit (+/-)	Capital reserve (+/-)	Retained profit (+/-)
C ., . (國藥產業投資有限公司)		2,907,223,542.90	-2,907,223,542.90	2,907,223,542.90	-2,907,223,542.90
C ., . (湖南漢森製藥股份有限公司)		60,158,451.41	-60,158,451.41	36,589,630.88	-36,589,630.88
		2,967,381,994.31	-2,967,381,994.31	2,943,813,173.78	-2,943,813,173.78


(2)

[illegible]


3.5.3



3.5.4



3.5.5



f

ff

2014

2014

30 —


[illegible]

2014

2014

. 41 — 

4.



Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
: Chen Qiyu
28 2014

4. APPENDICES

4.1 Financial statements

Consolidated balance sheet 30 September 2014

: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
C	3,648,549,469.86	3,067,413,633.64
	35,140,637.56	44,195,883.71
B	401,946,288.48	356,174,511.89
T	1,594,200,321.82	1,293,986,619.98
	283,453,667.80	202,300,884.24
	539,788.34	822,388.20
D	12,687,706.84	15,149,056.84
	301,255,615.46	387,987,436.17
	1,767,247,387.65	1,614,271,795.30
	2,974,503.76	4,242,198.12
T	8,047,995,387.57	6,986,544,408.09
Non-current assets:		
A	2,388,182,505.34	2,664,408,852.29
	11,313,383,889.81	8,940,474,119.19
	3,814,845,860.52	3,582,158,990.97
C	1,545,011,125.70	1,321,060,523.61
	5,853,113.77	4,231,968.29
D		
	2,637,903,401.92	2,590,492,325.70
D	74,997,201.63	48,950,334.57
	3,039,539,087.55	2,976,039,397.86
	27,984,014.39	30,589,235.50
D	92,619,324.69	88,091,330.24
	250,123,807.89	242,149,375.47
T	25,190,443,333.21	22,488,646,453.69
T	33,238,438,720.78	29,475,190,861.78

Consolidated balance sheet (*Continued*)
30 September 2014

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
-	2,288,206,111.79	1,383,300,726.59
B		
D		
B	122,798,217.82	145,588,393.35
T	1,176,237,922.27	990,861,493.44
	270,129,487.34	257,722,214.41
	268,603,358.24	253,056,428.28
T	412,747,932.00	288,904,858.86
	162,305,255.65	147,655,274.33
D	17,771,267.27	6,286,003.99
	1,565,007,659.98	1,712,026,741.35
A		
A		
	94,129,100.00	40,909,090.00
	60,593,840.46	51,810,029.11
T	6,438,530,152.82	5,278,121,253.71
Non-current liabilities:		
-	1,033,911,519.47	126,318,141.82
B	5,081,077,289.14	4,073,391,240.49
	387,553,457.88	404,467,334.87
A		
D	1,751,055,544.54	1,783,519,889.47
	161,252,621.61	144,858,843.98
T	8,414,850,432.64	6,532,555,450.63
T	14,853,380,585.46	11,810,676,704.34
Equity attributable to the owners (or equity attributable to shareholders):		
- ()	2,311,611,364.00	2,240,462,364.00
C	7,263,416,877.40	7,469,126,906.58
	1,485,373,176.37	1,485,373,176.37
	5,719,894,394.26	4,145,310,529.87
	-4,259,593.83	-8,088,493.79
T	16,776,036,218.20	15,332,184,483.03
	1,609,021,917.12	2,332,329,674.41
T	18,385,058,135.32	17,664,514,157.44
T	33,238,438,720.78	29,475,190,861.78

: C C f ff : D A
D :

Balance sheet of the Parent Company
30 September 2014

: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

: C : B T f :

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
C	1,370,322,227.18	928,131,985.71
B		
T		
	64,152,914.93	26,559,855.50
D	12,687,706.84	16,956,224.96
	2,078,641,754.87	1,874,849,219.04
	517,939.44	517,939.44
	698,000,000.00	245,000,000.00
T	4,224,322,543.26	3,092,015,224.65
Non-current assets :		
A	435,945,082.78	250,497,792.58
	13,265,406,462.70	5,130,347,780.08
	21,112,995.92	20,165,064.87
C		
D		
	2,825,153.33	3,059,034.52
D		
	3,624,944,639.39	4,062,847,282.90
T	17,350,234,334.12	9,466,916,954.95

Balance sheet of the Parent Company (*Continued*)
30 September 2014

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
-	450,000,000.00	360,000,000.00
B		
T		
	70,906,240.75	60,829,711.34
T	21,696,849.47	22,229,396.68
	141,440,958.60	144,354,519.49
D	1,062,450.00	
	501,554,011.99	99,612,423.54
	40,000,000.00	40,000,000.00
T	1,226,660,510.81	727,026,051.05
Non-current liabilities:		
-	284,000,000.00	125,000,000.00
B	5,081,077,289.14	4,073,391,240.49
-		
A		
D	1,010,170,447.97	
	1,825,000.00	2,050,000.00
T	6,377,072,737.11	4,200,441,240.49
T	7,603,733,247.92	4,927,467,291.54
Equity attributable to the owners (or equity attributable to shareholders):		
- ()	2,311,611,364.00	2,240,462,364.00
C	8,042,687,160.24	3,876,481,297.41
:		
	868,105,135.33	456,890,135.33
	2,748,419,969.89	1,057,631,091.32
T ()	13,970,823,629.46	7,631,464,888.06
T ()	21,574,556,877.38	12,558,932,179.60

: C f ff : D f A
D :



Consolidated Income Statement (*Continued*)

Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
T (“ ”)	745,109,456.40	485,087,273.74	2,103,998,492.33	1,349,217,433.21
:	103,392,523.69	64,843,016.85	309,981,421.35	167,041,671.55
(“ ”)	641,716,932.71	420,244,256.89	1,794,017,070.98	1,182,175,761.66
	557,028,104.62	337,663,263.12	1,574,583,864.38	950,584,632.64
/	84,688,828.09	82,580,993.77	219,433,206.60	231,591,129.02
(1)	0.24	0.15	0.69	0.42

Income Statement of the Parent Company

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
			450,000.00	
B			25,050.00	
A	45,422,145.86	25,499,951.01	132,373,353.42	82,756,689.01
	4,521,729.54	17,330,429.70	213,454.35	27,772,618.27
A				
(“–”)				
(“–”)	207,344,246.71	8,229,013.36	777,880,148.45	820,929,379.59
	205,756,805.32	6,268,813.36	672,369,606.74	1,839,063.36
(“–”)	157,400,371.31	–34,601,367.35	645,718,290.68	710,400,072.31
	139,209.23	76,900.00	289,209.23	236,049.11
			260,000.00	2,514,544.42
			64,209.23	5,725.77
T (“–”)	157,539,580.54	–34,524,467.35	645,747,499.91	708,121,577.00
(“–”)	157,539,580.54	–34,524,467.35	645,747,499.91	708,121,577.00
(1)				
(2)				
	123,670,800.00		119,691,936.66	51,779.40
T	281,210,380.54	–34,524,467.35	765,439,436.57	708,173,356.40

：C C f ff : D A D :

: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

[illegible]

Consolidated Statement of Cash Flow (*Continued*)
January – September 2014

Items	Current Amount (January – September)	Amount of the Last Period (January – September)
III. Cash flow generated from financing activities:		
Cash received from the sale of equity securities	1,445,949,451.00	2,088,710.98
Proceeds from the issuance of debt securities	38,269,850.07	2,088,710.98
Cash received from the sale of property, plant, and equipment	3,475,109,758.30	1,302,361,982.24
Cash received from the sale of investments	1,000,000,000.00	
Proceeds from the sale of subsidiaries	21,733,509.09	329,448,475.13
Proceeds from the sale of other assets	5,942,792,718.39	1,633,899,168.35
Cash received from the sale of investments in subsidiaries	1,623,242,732.68	1,221,891,677.53
Cash received from the sale of investments in associates	1,012,768,967.52	950,844,046.86
Proceeds from the sale of investments in other entities	133,554,721.22	231,783,996.47
Proceeds from the sale of investments in real estate	1,512,793,278.03	48,488,630.70
Proceeds from the sale of investments in other financial assets	4,148,804,978.23	2,221,224,355.09
Proceeds from the sale of investments in other non-current assets	1,793,987,740.16	-587,325,186.74
IV. Effects of exchange rate fluctuations on cash and cash equivalents	14,780,312.38	-25,426,268.76
V. Net increase of cash and cash equivalents	880,460,028.28	-1,902,809,425.34
Net increase of cash and cash equivalents	2,416,260,389.25	4,171,574,742.12
VI. Closing balance of cash and cash equivalents	3,296,720,417.53	2,268,765,316.78

: C f ff : D f A
D :

Statement of Cash Flow of the Parent Company
January – September 2014

: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

: C : B T f :

Items	Current Amount (January – September)	Amount of the Last Period (January – September)
I. Cash flow generated from operating activities:		
C	450,000.00	
	24,262,470.46	37,439,681.37
	24,712,470.46	37,439,681.37
C		
C	55,675,865.31	47,805,533.82
T	38,638,399.47	20,609,862.43
	28,772,270.22	31,711,001.63
	123,086,535.00	100,126,397.88
	-98,374,064.54	-62,686,716.51
II. Cash flow generated from investing activities:		
C		39,904,000.00
C	135,001,207.03	794,850,316.23
	150,000.00	96,000.00
	10,351,169.50	
	408,839,600.00	638,137,500.00
	554,341,976.53	1,472,987,816.23
C	3,334,618.53	1,762,713.09
C	1,780,579,380.37	709,566,469.16
	27,023,100.00	459,096,900.00
	20,000,000.00	
	1,830,937,098.90	1,170,426,082.25
	-1,276,595,122.37	302,561,733.98
III. Cash flow generated from financing activities:		
C	1,407,679,600.93	
C	850,000,000.00	255,115,078.77
C	1,000,000,000.00	
	4,754,495,093.76	1,904,031,173.98
	8,012,174,694.69	2,159,146,252.75
C	601,000,000.00	790,115,078.77
C	829,585,897.32	674,744,025.09
	4,365,392,837.67	2,109,471,293.35
	5,795,978,734.99	3,574,330,397.21
	2,216,195,959.70	-1,415,184,144.46
IV. Effects of exchange rate fluctuations on cash and cash equivalents	9,803,068.68	-22,851,531.32
V. Net increase of cash and cash equivalents	851,029,841.47	-1,198,160,658.31
	519,292,385.71	2,090,971,083.37
VI. Closing balance of cash and cash equivalents	1,370,322,227.18	892,810,425.06

: C : C f ff : D A

